Market Overview

Jefferies Maintains $36 PT On AUXL


Jefferies is maintaining its $36 PT on shares of Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL).

“Xiaflex continues to be the main stock driver for AUXL,” Jefferies writes. “We believe Xiaflex adoption is gated by reimbursement concerns rather than clinical concerns, and we anticipate steady Xiaflex sales growth in 2011 with sales acceleration in 2012.”

Auxilium Pharmaceuticals closed Friday at $22.32.

Posted-In: Auxilium Pharmaceuticals JefferiesAnalyst Ratings


Related Articles (AUXL)

View Comments and Join the Discussion!

Latest Ratings

TOLGoldman SachsInitiates Coverage On42.0
KBHGoldman SachsInitiates Coverage On36.0
YEXTSunTrust Robinson HumphreyMaintains28.0
LHCGSunTrust Robinson HumphreyMaintains160.0
DLRSunTrust Robinson HumphreyMaintains140.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Goldman Sachs Removes Express From 'Americas Buy List,' Raises PT To $20 (EXPR)

Morgan Keegan Maintains Education Realty Trust Outperform, Lowers PT To $8.50 (EDR)